Program
Please note that this conference will take place as an in-person event in Boston and will not live-stream content for virtual participation. The educational sessions, plenary sessions, concurrent sessions, and keynote lectures will be recorded and made available as an on-demand program after the conference. All presentations are scheduled to be live, in-person presentations at the date and time specified in the program.
*-Short talk from proffered abstract
Wednesday, October 11
- Educational Session 1: Patient-derived Models to Accelerate Drug Discovery
- Educational Session 2: Challenges and Prospects in the Analysis of Spatial and Single Cell Biology
- Welcome and Keynote Lectures
Thursday, October 12
- Plenary Session 1: Liquid Biopsies in the Clinic: Is It Ready for Prime Time?
- Plenary Session 2: The Journey of Antibody Drug Conjugate Development
- Spotlight on Proffered Papers 1
- Exhibit Show and Poster Session A
- Concurrent Session 1: T-cell Engaging Bispecific Antibodies in Solid Tumors
- Concurrent Session 2: Killing Shapeshifting Tumors: Leveraging Plasticity to Target Tumor Heterogeneity
- Concurrent Session 3: The Future of Tumor Agnostic Drug Development
Friday, October 13
- Plenary Session 3: KRAS
- Plenary Session 4: New Drugs on the Horizon
- Spotlight on Proffered Papers 2
- Exhibit Show and Poster Session B
- Concurrent Session 4: Targeting Stromal Cells in Cancer Immunotherapy
- Concurrent Session 5: Large-Scale Multicenter Platform Trials: Combine and Conquer
- Concurrent Session 6: Unmet Needs and Opportunities to Advance Therapies for Rare Cancers
- Chemistry in Cancer Research (CICR) Town Hall
Saturday, October 14
- Plenary Session 5: Targeting the DNA Damage Response: Lessons from the Past, Looking into the Future
- Concurrent Session 7: Glyco-immunology in Cancer Drug Development
- Concurrent Session 8: Targeted and Immunotherapy Approaches Against p53
- Concurrent Session 9: Advances in Targeted Protein Degradation and Induced Proximity
- Spotlight on Proffered Papers 3
- Exhibit Show and Poster Session C
- Concurrent Session 10: Next-generation Cytokine Engineering for Cancer
- Concurrent Session 11: Emerging T Cell Checkpoints Beyond PD1, CTLA4, and LAG3
- Concurrent Session 12: Drug Screening
Sunday, October 15
- Plenary Session 6: Expanding the Frontiers of T Cell Therapy
- Plenary Session 7: NK Cell Therapeutics
- Plenary Session 8: Emerging Role of Therapeutic Vaccines and mRNA in Cancer
WEDNESDAY, OCTOBER 11
Registration
12-7 p.m. | Level 2, exhibit hall D lobby
Educational Session 1: Patient-derived Models to Accelerate Drug Discovery
Session Cochairs: NATHAN P. COUSSENS, Frederick national laboratories for Cancer Research, Frederick, maryland and Annamaria Rapisarda, Leidos Biomedical Research, Frederick, MarylanD
2-3:30 p.m. | Level 3, ballroom AB
Patient-derived tumor organoids to probe the cancer-immune interface
Krijn Dijkstra, Netherlands Cancer Institute, Amsterdam, Netherlands
High-throughput screening of approved and investigational anticancer agents with patient-derived organoids representing a wide range of histologies
Annamaria Rapisarda
Surgical applications of organoid technology: Bench to bedside in therapeutic oncology
Konstantinos Votanopoulos, Wake Forest University, Winston-Salem, North Carolina
Interpretation of patient-specific ex vivo immunotherapy response for ovarian cancer*
Willemijn Vader, VitroScan, Leiden, Netherlands
Panel Discussion
Break
3:30-3:45 P.M. | lEVEL 3, bALLROOM foyer
Educational Session 2: Challenges and Prospects in the Analysis of Spatial and Single cell biology
Session Cochairs: Manfred Claasen, University of Tübingen, Tübingen, Germany, and Eytan Ruppin, National Cancer Institute, Bethesda, MarylanD
3:45-5:15 p.m. | Level 3, ballroom ab
Inference of intercellular signaling activities during tumor immune evasion in spatial and single-cell transcriptomics data
Peng Jiang, National Cancer Institute, Bethesda, Maryland
Lung cancer evolution in space and time
Nicholas McGranahan, UCL London Cancer Institute, London, England
Decoding spatially defined ecosystems in cancer with digital cytometry
Aaron M. Newman, Stanford University, Stanford, California
Single-cell spatial analysis reveals microenvironmental features that contribute to immune discrepancies between adult and pediatric nasopharyngeal carcinomas*
Lanqi Gong, National Cancer Institute, Bethesda, Maryland
Panel Discussion
Break
5:15-5:30 p.m. | level 3, ballroom Foyer
Welcome and Keynote Lectures
5:30-7:20 p.m. | Level 3, Ballroom AB
Welcome and Opening Remarks
Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
Tim F. Greten, National Cancer Institute, Bethesda, Maryland
E. G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands
(Re)emerging principles for drug treatment of cancer
William G. Kaelin, Jr., Dana-Farber Cancer Institute, Boston, Massachusetts
Understanding mechanisms of action of modern anticancer drugs
Fabrice André, Institut Gustave Roussy, Villejuif, France
Opening Reception
7:30-9:30 p.m. | Level 3, boylston street hallway
THURSDAY, OCTOBER 12
Registration
7 a.M.-5 P.M. | lEVEL2, EXHIBIT hALL D LOBBY
Continental Breakfast
7-8 a.m. | LEVEL 3, BOYLSTON STREET HALLWAY
Plenary Session 1: Liquid Biopsies in the Clinic: Is it Ready for Prime Time?
Session Cochairs: Catherine Alix-Panabières, University of Montpellier, Montpellier, France, and Klaus Pantel, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
8-9:40 a.m. | lEVEL 3, BALLROOM AB
European Liquid Biopsy Consortia: From discovery to clinical implementation
Klaus Pantel
The power of circulating tumor cells in immuno-oncology
Catherine Alix-Panabières
Engineering technologies for complex clinical laboratories: Lessons learned with extracellular vesicles
Shannon L. Stott, Harvard Medical School, Boston, Massachusetts
Panel Discussion
Break
9:40-10 a.m. | LEVEL 3, BALLROOM FOYER
Plenary Session 2: The Journey of Antibody Drug Conjugate Development
Session Cochairs: E. G. ELISABETH DE VRIES, UNIVERSITY MEDICAL CENTRE GRONINGEN, GRONINGEN, NETHERLANDS and Patricia M. LoRusso, Yale Cancer Center, New Haven, Connecticut
10-11:40 a.m. | lEVEL 3, bALLROOM AB
Refining our understanding of ADCs: Drug development insights from 40 years of data
Raffaele Colombo, Zymeworks, Inc., Vancouver, British Columbia, Canada
Antibody drug conjugates: History does not repeat itself, but it does sometimes rhyme
Anthony W. Tolcher, NEXT Oncology, San Antonio, Texas
Optimizing the safety of antibody-drug conjugates for the treatment of cancer
Paolo Tarantino, Dana-Farber Cancer Institute, Boston, Massachusetts
Panel Discussion
Spotlight on Proffered Papers 1
Session Chair: Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
11:45 a.m.-12:15 p.m. | Level 3, ballroom ab
Repotrectinib in patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial*
Jessica J. Lin, Massachusetts General Hospital, Boston, Massachusetts
PRISM high-throughput screening of antibody-drug conjugates uncovers clinically relevant targets*
Jillian N. Eskra, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis*
Xiuning Le, The University of Texas MD Anderson Cancer Center, Houston, Texas
Exhibit Show
12-4 p.m. | Level 2, exhibit hall d
Poster Session A
12:30-4 p.m. | Level 2, exhibit hall d
View titles and presenters in Poster Session A
Concurrent Sessions 1-3
4-5:40 p.m.
Concurrent session 1: T-cell engaging bispecific antibodies in solid tumors
Session Cochairs: Stéphane Champiat, Institut Gustave Roussy, Villejuif, France, and James H. Doroshow, National Cancer Institute, Bethesda, Maryland
level 3, rooms 302-304
Preclinical development of DuoBody®-CD3xB7H4, a novel CD3 bispecific antibody for the treatment of solid cancers
Farshid Alemdehy, Genmab, Copenhagen, Denmark
Emerging insights from the tebentafusp clinical program
David Berman, Immunocore, Rockville, Maryland
Next-generation, half-life extended TCR Bispecifics for targeting PRAME and beyond
Cedrik M. Britten, Immatics Biotechnologies, Munich, Germany
Panel Discussion
Concurrent session 2: Killing Shapeshifting Tumors: Leveraging Plasticity to Target Tumor Heterogeneity
Session Cochairs: Daniel S. Tan, National Cancer Centre Singapore, Singapore, and Anish Thomas, National Cancer Institute, Bethesda, Maryland
level 3, ballroom c
The role of extrachromosomal DNA amplifications during cancer progression
Roel Verhaak, Amsterdam University Medical Center, Amsterdam, Netherlands
Small cell lung cancer plasticity shaped by extrachromosomal DNA
Anish Thomas
Targeting the evolutionary drivers of EGFR mutated non-small cell lung cancer
Daniel S. Tan
Panel Discussion
Concurrent session 3: The Future of Tumor Agnostic Drug Development
Session Cochairs: Jordi Rodón ahnert, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Alison Schram, Memorial Sloan Kettering Cancer Center, New York, New York
level 3, ballroom ab
Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study
Alison Schram
Unleashing the power of precision: Exploring ADCs and beyond in novel tumor-agnostic drug development
Vivek Subbiah, Sarah Cannon Research Institute, Nashville, Tennessee
Design of next generation precision medicine trials using artificial intelligence
Christophe Le Tourneau, Institute Curie, Paris, France
Panel Discussion
FRIDAY, OCTOBER 13
rEGISTRATION
7 a.m.-5 p.m. | Level 2, Exhibit Hall D lobby
Continental Breakfast
7-8 a.m. | level 3, boylston street hallway
Plenary Session 3: KRAS
Session Cochairs: Karen M. Cichowski, Brigham and Women’s Hospital, Boston, Massachusetts and David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas
8-9:25 a.m. | Level 3, ballroom ab
KRAcking RAS: The current state
David S. Hong
Promising combinatorial strategies for KRAS mutant cancers
Karen M. Cichowski
Targeting RAS-addicted cancers with investigational RAS(ON) inhibitors
W. Clay Gustafson, Revolution Medicines, Redwood City, California
Clinical translational considerations for co-targeting KRAS and immune checkpoints
James G. Christensen, Mirati Therapeutics, San Diego, California
Panel Discussion
Break
9:25-9:40 a.m. | level 3, Ballroom foyer
Plenary Session 4: New Drugs on the Horizon
Session Cochairs: Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas, Tim F. Greten, National Cancer Institute, Bethesda, MarylanD, and E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands
9:40-11:45 a.m. | Level 3, ballroom ab
Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors*
Jordi Rodon Ahnert, The University of Texas MD Anderson Cancer Center, Houston, Texas
Discovery of HRO761, a novel, first-in-class clinical stage WRN inhibitor with potent and selective anti-tumor activity in cancers with microsatellite instability*
Marta Cortes-Cros, Novartis Institutes for bioMedical Research, Basel, Switzerland
MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A*
Timothy Yap
Discovery of covalent NRAS inhibitors targeting the palmitoylation site through imaging-based high-throughput screening*
Zhao Wang, Covant Therapeutics, Boston, Massachusetts
Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001*
Alexander I. Spira, NEXT Oncology, Fairfax, Virginia
Discovery of VVD-065, a first-in-class allosteric molecular glue of the Keap1-Cul3 E3-ligase complex for the treatment of NRF2-activated cancers*
Matt Patricelli, Vividion Therapeutics, San Diego, California
Spotlight on Proffered Papers 2
Session Chair: Tim F. Greten, National Cancer Institute, Bethesda, MarylanD
11:50 a.m.-12:20 p.m. | Level 3, Ballroom ab
Novel strategy for RAS-pathway targeting: Initial results from a phase 1b/2 clinical trial of the oral HDAC inhibitor bocodepsin (OKI-179) combined with binimetinib in patients with RAS-pathway mutated solid tumors and NRAS-mutated melanoma*
Rodabe N. Amaria, The University of Texas MD Anderson Cancer Center, Houston, Texas
First-in-human dose-expansion study of NBF-006, a novel investigational siRNA targeting GSTP, in patients with KRAS-mutated non-small cell lung cancer*
Alexander I. Spira, NEXT Oncology, Fairfax, Virginia
Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF) inhibitor treatment*
Pasi A. Jänne, Dana Farber Cancer Institute, Boston, Massachusetts
Exhibit Show
12-4 p.m. | Level 2, Exhibit hall d
Poster Session B
12:30-4 p.m. | Level 2, exhibit hall d
View titles and presenters in Poster Session B
Concurrent Sessions 4-6
4-5:40 p.m.
Concurrent session 4: Targeting Stromal Cells in Cancer Immunotherapy
Session Cochairs: Ellen Puré, University of Pennsylvania, Philadelphia, Pennsylvania, and David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
level 3, ballroom c
CAF-immune interactions in the tumor microenvironment
Ruth Scherz-Shouval, Weizmann Institute of Science, Rehovot, Israel
Dichotomous roles of the pancreatic tumor microenvironment
Claus Jorgensen, CRUK Manchester Institute, University of Manchester, Manchester, England
Mechanisms and consequences of pancreatic cancer stromal evolution
Mara H. Sherman, Memorial Sloan Kettering Cancer Center, New York, New York
Panel Discussion
Concurrent session 5: Large-Scale Multicenter Platform Trials: Combine and Conquer
Session Cochairs: Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, Texas and Beverly A. Teicher, National Cancer Institute, Bethesda, Maryland
level 3, ballroom aB
NCI ComboMATCH
Funda Meric-Bernstam
Platform Neoadjuvant Biomarker-Driven Trial in Patients with Gastroesophageal Adenocarcinoma
Elena R. Elimova, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
DRUP (Drug Rediscovery Protocol): Facilitating personalized access to existing anticancer drugs
Henk M. W. Verheul, Erasmus MC Rotterdam, Rotterdam, Netherlands
Panel Discussion
Concurrent session 6: Unmet Needs and Opportunities to Advance Therapies for Rare Cancers
Session Cochairs: Timothy Heffernan, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Brigitte C. Widemann, National Cancer Institute, Bethesda, Maryland
Level 3, Rooms 302-304
Realizing clinical trials for rare pediatric cancers
Brigitte C. Widemann
New approaches to targeting rare fusion driven pediatric cancers
Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
Power of data and AI in drug development for rare cancers
Bissan Al-Lazikani, The University of Texas MD Anderson Cancer Center, Houston, Texas
Panel Discussion
Chemistry in Cancer Research (CICR) Town Hall:
Approaches to Targeting the Guardian of the Genome, p53 [NOT CME ELIGIBLE]
6-7:30 p.m. | Level 3, Room 312
Discovery and development of PC14586, a first-in-class small molecule reactivator of p53 Y220C
Leila Alland, PMV Pharmaceuticals, Cranbury, New Jersey
Design-rules for stapled peptides with in vivo activity and their application to Mdm2/X antagonists
Charles Johannes, Consultant, EPOC Scientific, Boston, Massachusetts
AceTAC, a novel, innovative, and targeted protein acetylation modality
Md Kabir, Icahn School of Medicine at Mount Sinai, New York, New York
Panel Discussion
SATURDAY, OCTOBER 14
Registration
7 A.M.-5 P.M. | Level 2, exhibit hall d lobby
Continental Breakfast
7-8 a.m. | level 3, boylston street hallway
Plenary Session 5: Targeting the DNA Damage Response: Lessons from the Past, Looking into the Future
Session Cochairs: S. Percy Ivy, National Cancer Institute, Bethesda, MarylanD, and Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
8-9:40 a.m. | Level 3, Ballroom ab
Learning from the past, looking to the future in targeting the DNA damage response
Thomas Helleday, Karolinska Institutet, Stockholm, Sweden
New opportunities to target the ATR dependency of cancer cells
Lee Zou, Duke University School of Medicine, Durham, North Carolina
Targeting adaptive responses in cancer through SMMART clinical trials
Gordon B. Mills, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon
Panel Discussion
Break
9:40-10 a.m. | Level 3, ballroom foyer
Concurrent Sessions 7-9
10-11:40 a.m.
concurrent session 7: Glyco-immunology in Cancer Drug Development
Session Cochairs: Li Peng, Palleon Pharmaceuticals, Waltham, Massachusetts, and Matthew G. Vander Heiden, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts
Level 3, rooms 302-304
Stromal cell sialylation as an immunosuppressive target in the CRC tumor microenvironment
Aideen E. Ryan, University of Galway, Galway, Ireland
Antibody-lectin chimeras for glyco-immune checkpoint blockade
Jessica C. Stark, Stanford University, Stanford, California
Engineering human sialidase as novel cancer therapeutics by targeting sialoglycans
Li Peng
Panel Discussion
concurrent session 8: Targeted and Immunotherapy Approaches Against p53
Session Cochairs: Ecaterina E. Dumbrava, The University of Texas MD Anderson Cancer Center, Houston, Texas, and James C. Yang, National Cancer Institute, Bethesda, Maryland
level 3, ballroom c
Title to be announced
Aparna Parikh, Massachusetts General Hospital, Boston, Massachusetts
Targeting MDM2 in solid tumors
Ecaterina Dumbrava
T-cells targeting common p53 neoantigens in epithelial cancers
James C. Yang
Panel Discussion
concurrent session 9: Advances in Targeted Protein Degradation and Induced Proximity
Session Cochairs: Danette L. Daniels, Foghorn Therapeutics, Cambridge, Massachusetts, and Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, Massachusetts
level 3, ballroom ab
Molecular glue degraders
Benjamin L. Ebert
Reimagining druggability using chemoproteomic platforms
Daniel K. Nomura, University of California, Berkeley, California
Expanding the druggable genome with molecular glues
Mary Matyskiela, Neomorph, Inc., San Diego, California
Panel Discussion
Spotlight on Proffered Papers 3
Session Chair: E.G. Elisabeth de Vries, University Medical Centre Groningen, Groningen, Netherlands
11:45 a.m.-12:15 p.m. | level 3, ballroom ab
Determining the mechanism of action of the anti-ENTPD2 antibody, KAZ954*
Deborah Knee, Novartis Institutes for BioMedical Research, San Diego, CA
Large-scale organoid panel drug screening to short-track clinically-relevant output*
Mariusz Madej, Crown Bioscience, Leiden, Netherlands
Discovery and clinical evaluation of a potent and selective A2A/2B dual receptor antagonist*
Duane DeMong, Merck & Company, Boston, Massachusetts
Exhibit Show
12-4 p.m. | Level 2, exhibit hall d
Poster Session C
12:30-4 p.m. | Level 2, exhibit hall d
View titles and presenters in Poster Session C
Concurrent Sessions 10-12
4-5:40 p.m.
Concurrent session 10: Next-generation Cytokine Engineering for Cancer
Session Cochairs: Naiyer A. Rizvi, Synthekine, Menlo Park, California, and Jamie B. Spangler, Johns Hopkins Medicine, Baltimore, Maryland
level 3, rooms 302-304
Tumor-specific delivery of immune-activating cytokine/antibody fusion proteins
Jamie B. Spangler
Engineered IL-12 delivery to the tumor matrix to achieve enhanced efficacy and safety
Jun Ishihara, Imperial College London, London, England
REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy
Tong Zhang, Regeneron Pharmaceuticals, Inc., Tarrytown, New York
Panel Discussion
concurrent session 11: Emerging T Cell Checkpoints Beyond PD1, CTLA4, and LAG3
Session Cochairs: Ana C. Anderson, Brigham and Women’s Hospital, Boston, Massachusetts, and Maria Jose de Miguel, START Madrid, Madrid, Spain
Level 3, ballroom c
Targeting adenosine receptor and transport for cancer immunotherapy
John Stagg, University of Montreal, Montreal, Quebec City, Canada
PVRIG: An emerging target in the IO landscape
Drew W. Rasco, South Texas Accelerated Research Therapeutics, San Antonio, Texas
Role of tigit in regulating tumor immune infractions
Lloyd Bod, Massachusetts General Cancer Center, Boston, Massachusetts
Panel Discussion
concurrent session 12: Drug Screening
Session Cochairs: Matthew Garnet, Wellcome Sanger Institute, Cambridge, England, and Barry R. O’Keefe, National Cancer Institute, Bethesda, Maryland
Level 3, ballroom ab
Integrating natural product samples back into drug screening programs
Barry R. O’Keefe
Investigating adaptive phenotypic plasticity as an early cancer driver in response to anti-cancer treatment for improved treatment strategies
Alejandra Bruna, The Institute of Cancer Research, London, England
Large-scale pan-cancer screen to identify actionable combinations
Claire Crafter, AstraZeneca, Cambridge, England
From targeted phenotypic screen to NXP800: A clinical stage activator of the integrated stress response for the treatment of ARID1A-mutated ovarian carcinoma
Paul Workman, The Institute of Cancer Research, London, England
Panel Discussion
SUNDAY, OCTOBER 15
rEGISTRATION
7 a.m.-1 p.m. | level 2, Exhibit hall d lobby
Continental Breakfast
7-8 a.m. | level 3, boylston street hallway
Plenary Session 6: Expanding the Frontiers of T Cell Therapy
Session Cochairs: Benjamin C. Creelan, Moffitt Cancer Center, Tampa, FLorida, and Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain
8-9:40 a.m. | level 3, ballroom ab
TIL therapy for solid tumors: Next steps
Elena Garralda
Next generation CAR-Ts for solid tumors: A focus into the progress expected for CARs in solid tumors
Salman R. Punekar, NYU Langone Health Perlmutter Cancer Center, New York, New York
Future targets for cell therapy in epithelial cancers
Benjamin C. Creelan
IMA203 TCR-T targeting PRAME demonstrates potent anti-tumor activity in patients with different types of metastatic solid tumors*
Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Panel Discussion
Break
9:40-10 a.m. | level 3, ballroom foyer
Plenary Session 7: NK Cell Therapeutics
Session Cochairs: Juanita S. Lopez, The Royal Marsden and Institute of Cancer Research, Sutton, England, and Jeffrey S. Miller, University of Minnesota Masonic Comprehensive Cancer Center, Minneapolis, Minnesota
10-11:40 a.m. | level 3, ballroom AB
Novel NK cell engineering approaches for solid tumors
Rizwan Romee, Dana-Farber Cancer Institute, Boston, Massachusetts
Title to be announced
Evren Alici, Karolinska Institutet, Huddinge, Sweden
Targeting off-the-shelf NK cell therapy to treat cancer
Jeffrey S. Miller
Panel Discussion
Break
11:40 a.m.-12 p.m. | LEVEL 3, BALLROOM FOYER
Plenary Session 8: Emerging Role of Therapeutic Vaccines and mRNA in Cancer
Session Cochairs: Karine Breckpot, Vrije University Brussels, Brussels, Belgium and Jason J. Luke, UPMC Hillman Cancer Center, Pittsburgh, PennsylvaniA
12-1:40 p.m. | LEVEL 3, BALLROOM AB
mRNA-4157 individualized neoantigen therapy: mRNA therapeutics coming of age in cancer
Robert S. Meehan, Moderna, Cambridge, Massachusetts
Leveraging mRNA to design a next-generation cell-based therapeutic cancer vaccine
Karine Breckpot
Personalized cancer vaccines targeting neoantigens for patients with cancer: An update on successes, challenges, and opportunities
Patrick Ott, Dana-Farber Cancer Institute, Boston, Massachusetts
Panel Discussion